Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers.


Journal

Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611

Informations de publication

Date de publication:
06 Jul 2020
Historique:
received: 07 04 2020
revised: 27 04 2020
accepted: 11 05 2020
pubmed: 18 6 2020
medline: 9 7 2021
entrez: 18 6 2020
Statut: ppublish

Résumé

The present study aimed to analyze treatment outcomes after induction chemotherapy followed by chemoradiotherapy (CRT) using volumetric-modulated arc therapy (VMAT) in patients with stage IVA-B oropharyngeal cancer (OPC) or hypopharyngeal cancer (HPC), with long-term observation, including examination of larynx preservation. A total of 60 patients with stage IVA-B OPC or HPC, who underwent induction TPF chemotherapy (a combination regimen consisting of docetaxel, cisplatin, and 5-fluorouracil) followed by CRT using VMAT were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated and compared. Univariate and multivariate analyses were performed to determine statistical differences in OS and LEDFS. The median follow-up period at the time of evaluation was 61 months. Twenty-six (43%) patients had OPC and 34 (57%) had HPC. The 5-year OS, PFS, LEDFS, and LRC rates were 57%, 52%, 52%, and 68%, respectively. Response to TPF therapy was the only significant predictive factor of OS and LEDFS in multivariate analyses. Regarding long-term toxicities, grade ≥ 2 late toxicities accounted for 15%. No patients experienced grade ≥ 3 xerostomia, and 5% of all patients developed grade 3 dysphagia. With long-term observation, the OS, PFS, and LEDFS rates were relatively good, and the incidence of late toxicities was low. TPF followed by CRT using VMAT was feasible and more effective in those who responded to induction chemotherapy.

Identifiants

pubmed: 32548612
pii: 5858247
doi: 10.1093/jrr/rraa033
pmc: PMC7336564
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

554-562

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Références

Jpn J Clin Oncol. 2017 Nov 1;47(11):1031-1037
pubmed: 28973501
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer. 2011 Oct 1;117(19):4447-51
pubmed: 21437891
J Natl Cancer Inst. 2015 Dec 16;108(4):
pubmed: 26681800
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
Jpn J Clin Oncol. 2016 Apr;46(4):344-9
pubmed: 26826721
Laryngoscope. 1995 Apr;105(4 Pt 1):397-406
pubmed: 7715386
Cancer Med. 2020 Mar;9(5):1671-1682
pubmed: 31943834
Int J Clin Oncol. 2019 Jul;24(7):789-797
pubmed: 30796560
Front Oncol. 2019 Jan 22;9:6
pubmed: 30723701
Head Neck Surg. 1987 Sep-Oct;10(1):4-13
pubmed: 3449480
Lancet Oncol. 2011 Feb;12(2):153-9
pubmed: 21233014
Anticancer Res. 2016 Dec;36(12):6625-6630
pubmed: 27919993
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):410-5
pubmed: 18635320
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303
pubmed: 19306746
J Natl Cancer Inst. 2009 Feb 4;101(3):142-52
pubmed: 19176454
Front Oncol. 2019 Jul 10;9:625
pubmed: 31355142
Int J Clin Oncol. 2015 Jun;20(3):431-7
pubmed: 24993675
Cancer. 2008 Nov 15;113(10):2797-806
pubmed: 18839393
Laryngoscope. 2017 Aug;127(8):1791-1796
pubmed: 27888508

Auteurs

Katsumaro Kubo (K)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Yuji Murakami (Y)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Masahiro Kenjo (M)

Hiroshima High-Precision Radiotherapy Cancer Center, 2-2 Futabanosato Higashi-ku Hiroshima-shi, Hiroshima 732-0057, Japan.

Nobuki Imano (N)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Yuki Takeuchi (Y)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Ikuno Nishibuchi (I)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Tomoki Kimura (T)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Daisuke Kawahara (D)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Tsutomu Ueda (T)

Department of Otorhinolaryngology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Sachio Takeno (S)

Department of Otorhinolaryngology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.

Yasushi Nagata (Y)

Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan.
Hiroshima High-Precision Radiotherapy Cancer Center, 2-2 Futabanosato Higashi-ku Hiroshima-shi, Hiroshima 732-0057, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH